Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241371 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00241371: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT00241371 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00241371, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.
Interventions
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Why NCT00241371 stopped before completion
NCT00241371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Clofarabine is the first listed.
NCT00241371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00241371 about?
NCT00241371 is a clinical study titled "A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma". To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.
What is the current status of trial NCT00241371?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2005-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00241371?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00241371?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00241371's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia